TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12118024

Group type: EXPERIMENTAL
Intervention: Trastuzumab plus chemotherapy
Number of subjects: 400

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 400
Study: 10205954

Group type: EXPERIMENTAL
Intervention: NMAB‐urea
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: NMAB
Number of subjects: 150

Group type: COMPARATOR
Intervention: Isotonic saline (control)
Number of subjects: 150
Study: 7792498

Group type: EXPERIMENTAL
Intervention: Flurazepam 30 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 2145874

Group type: EXPERIMENTAL
Intervention: UK 69,578 (atriopeptidase inhibitor) administered as an intravenous infusion over 20 min
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: UK 69,578 (atriopeptidase inhibitor)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 620911

Group type: EXPERIMENTAL
Intervention: Cimetidine (0.8 to 1.2 g daily for 2 to 6 weeks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hospitalization (2 to 3 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cimetidine therapy cessation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chronic or intermittent cimetidine therapy
Number of subjects: 0
Study: 30957985

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (n=59)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Usual care (n=63)
Number of subjects: 122
Study: 30347090

Group type: EXPERIMENTAL
Intervention: Protocolized weaning via early extubation to noninvasive ventilation (n=182)
Number of subjects: 364

Group type: COMPARATOR
Intervention: Protocolized standard weaning (continued invasive ventilation until successful spontaneous breathing trial, followed by extubation) (n=182)
Number of subjects: 364

Group type: COMPARATOR
Intervention: Protocolized standard weaning (n=182)
Number of subjects: 364
Study: 27803139

Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: TNF-α inhibitors (Infliximab and Etanercept)
Number of subjects: 60
Study: 24673513

Group type: EXPERIMENTAL
Intervention: Benvitimod (0.5-2.0%) cream, doses escalated from 5 to 30 mg daily, applied once or twice daily
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Benvitimod (5 mg q.d and b.i.d)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 56
Study: 22988684

Group type: EXPERIMENTAL
Intervention: In-office treatment with desensitizing paste containing 8% arginine and calcium carbonate, followed by brushing with desensitizing toothpaste containing 8% arginine, calcium carbonate with 1450 ppm fluoride for 24 weeks.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Nupro-M pumice prophylaxis paste, followed by brushing with non-desensitizing toothpaste containing 1450 ppm fluoride for 24 weeks.
Number of subjects: 100
Study: 20174763

Group type: EXPERIMENTAL
Intervention: Thienopyridines
Number of subjects: 10735

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 10735

Group type: EXPERIMENTAL
Intervention: Picotamide
Number of subjects: 10735

Group type: COMPARATOR
Intervention: Antiplatelet treatment (overall)
Number of subjects: 10735
Study: 17431110

Group type: EXPERIMENTAL
Intervention: Lonafarnib (Farnesyl transferase inhibitor)
Number of subjects: 0
Study: 15867580

Group type: EXPERIMENTAL
Intervention: 5‐ASA MMx (1.2 g three times per day)
Number of subjects: 79

Group type: COMPARATOR
Intervention: 5‐ASA enema (4 g)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: 5‐ASA MMx
Number of subjects: 79

Group type: COMPARATOR
Intervention: 5‐ASA enema
Number of subjects: 79
Study: 16679206

Group type: EXPERIMENTAL
Intervention: Long buccal-segment group (canines, both premolars, and first molars)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Short buccal-segment group (only maxillary first molars)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study: 10826565

Group type: EXPERIMENTAL
Intervention: High sodium diet with L-NMMA infusion (1.8 mg/kg over 30 min)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Low sodium diet with L-NMMA infusion (1.8 mg/kg over 30 min)
Number of subjects: 7
Study: 8858747

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (5 g/day)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Carbohydrate-reduced diet (84 g/day)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204
Study: 1515637

Group type: EXPERIMENTAL
Intervention: rhu GM‐CSF (250 micrograms/m2)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study: 6507509

Group type: EXPERIMENTAL
Intervention: Diuretics continued throughout pregnancy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Diuretics discontinued immediately
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study: 30389202

Group type: EXPERIMENTAL
Intervention: Transition readiness for talking with providers
Number of subjects: 251
Study: 30138016

Group type: EXPERIMENTAL
Intervention: CHAT intervention (15-min brief motivational interviewing)
Number of subjects: 294

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 294
Study: 27463412

Group type: EXPERIMENTAL
Intervention: Low-lactose skimmed milk enriched with 40 mg/100 mL of eicosapentaenoic acid (EPA) + docosahexaenoic acid (DHA), 0.54 g/100 mL oleic acid, and vitamins (n = 63)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Semiskimmed milk enriched with vitamins A and D (n = 54)
Number of subjects: 117
Study: 25373811

Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 22674807

Group type: EXPERIMENTAL
Intervention: Thalidomide during induction, between transplantations, and during consolidation and maintenance (TT2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bortezomib, thalidomide, dexamethasone (VTD) during the first year of maintenance and thalidomide, dexamethasone (TD) for 2 more years (TT3A)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bortezomib, lenalidomide, dexamethasone (VRD) maintenance for 3 years (TT3B)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no thalidomide) in TT2
Number of subjects: 0
Study: 19609570

Group type: EXPERIMENTAL
Intervention: Physical activity intervention (home-based aerobic and light resistance training program, weekly group sessions)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Number of subjects: 100
Study: 18756746

Group type: EXPERIMENTAL
Intervention: Structural resonance electromagnetic therapy (SREMT) in the basic group
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard drug and physiotherapeutic treatment
Number of subjects: 120
Study: 15925962

Group type: EXPERIMENTAL
Intervention: Sublingual buprenorphine
Number of subjects: 53

Group type: COMPARATOR
Intervention: Oral methadone
Number of subjects: 53

Group type: COMPARATOR
Intervention: Sublingual buprenorphine and Oral methadone
Number of subjects: 53
Study: 12872590

Group type: EXPERIMENTAL
Intervention: Er:YAG laser treatment (100 mJ/pulse and 10 Hz)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control group (untreated implants)
Number of subjects: 2
Study: 10561978

Group type: EXPERIMENTAL
Intervention: TIVA with propofol and ketamine (n = 28)
Number of subjects: 58

Group type: COMPARATOR
Intervention: EIGA with isoflurane (n = 30)
Number of subjects: 58
Study: 8920391

Group type: EXPERIMENTAL
Intervention: Oral midazolam
Number of subjects: 0
Study: 1906441

Group type: EXPERIMENTAL
Intervention: Chronic low-dose TRH therapy
Number of subjects: 30
Study: 30902753

Group type: EXPERIMENTAL
Intervention: 2 g of oral tranexamic acid (TXA) 2 h preoperatively
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: 2 g of oral tranexamic acid (TXA) 4 h postoperatively
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: 2 g of oral tranexamic acid (TXA) at 4, 10, and 16 h postoperatively
Number of subjects: 151
Study: 28532137

Group type: EXPERIMENTAL
Intervention: Metoclopramide (10 mg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ondansetron (4 mg)
Number of subjects: 60
Study: 25784174

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 179

Group type: COMPARATOR
Intervention: Lisinopril
Number of subjects: 179
Study: 23260261

Group type: EXPERIMENTAL
Intervention: Ranibizumab (RBZ) 0.3 mg
Number of subjects: 789

Group type: EXPERIMENTAL
Intervention: Ranibizumab (RBZ) 0.5 mg
Number of subjects: 789

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 789

Group type: EXPERIMENTAL
Intervention: Ranibizumab (RBZ)
Number of subjects: 789

Group type: EXPERIMENTAL
Intervention: Crossover to 0.5 mg RBZ from sham at month 6
Number of subjects: 789
Study: 21800642

Group type: EXPERIMENTAL
Intervention: Experimental Group (EG) - 6 phone calls from a nurse specialized in tobacco cessation counselling
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control Group (not explicitly mentioned)
Number of subjects: 40
Study: 18771521

Group type: EXPERIMENTAL
Intervention: Real rTMS (n = 14)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Sham rTMS (n = 12)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Real rTMS
Number of subjects: 26

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 26
Study: 17644340

Group type: EXPERIMENTAL
Intervention: Encapsulated phytosterol esters (2.6 g for 12 weeks)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 15486748

Group type: EXPERIMENTAL
Intervention: Polyethylene glycol solution
Number of subjects: 33

Group type: COMPARATOR
Intervention: Water
Number of subjects: 33
Study: 11562614

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Tobramycin for inhalation
Number of subjects: 246
Study: 11233386

Group type: EXPERIMENTAL
Intervention: Prazosin GITS
Number of subjects: 119

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 119
Study: 8163364

Group type: EXPERIMENTAL
Intervention: Estraderm TTS 50 patches
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 20
Study: 2964845

Group type: EXPERIMENTAL
Intervention: Omnipaque
Number of subjects: 50

Group type: COMPARATOR
Intervention: Gastrografin
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both Omnipaque and Gastrografin
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Enteric follow‐through procedures
Number of subjects: 50
Study: 31342199

Group type: EXPERIMENTAL
Intervention: Mechanistic model of the immune response with T-regulatory (Treg) cell mediated tolerance adjustment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treg-adjusted model
Number of subjects: 0
Study: 28882773

Group type: EXPERIMENTAL
Intervention: Extracorporeal shockwave treatment (ESWT) plus specific exercise programme
Number of subjects: 42

Group type: COMPARATOR
Intervention: Exercise programme alone
Number of subjects: 42
Study: 25424501

Group type: EXPERIMENTAL
Intervention: FL3X behavioural intervention (minimum three sessions)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 61
Study: 24241957

Group type: EXPERIMENTAL
Intervention: Home-based HIV testing by trained lay counsellors using rapid tests (SD Bioline and Sensa)
Number of subjects: 3986

Group type: COMPARATOR
Intervention: Laboratory-based ELISA testing as the gold standard
Number of subjects: 3986
Study: 20673296

Group type: EXPERIMENTAL
Intervention: Partial implant-supported prosthesis
Number of subjects: 189

Group type: COMPARATOR
Intervention: No implants (control group)
Number of subjects: 189
Study: 19262561

Group type: COMPARATOR
Intervention: Caltrate D (1 pill daily)
Number of subjects: 150
Study: 16412224

Group type: EXPERIMENTAL
Intervention: Statin treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CABG patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Epicardial fat
Number of subjects: 0
Study: 15319704

Group type: EXPERIMENTAL
Intervention: Ropinirole (1.45 mg/d mean dosage)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Levodopa sustained release (190 mg/d mean dosage)
Number of subjects: 11
Study: 11167169

Group type: EXPERIMENTAL
Intervention: Epidural infusion with fentanyl (19.2+/‐5.2 microg x h(‐1))
Number of subjects: 20

Group type: COMPARATOR
Intervention: Epidural infusion without fentanyl
Number of subjects: 20
Study: 9024025

Group type: EXPERIMENTAL
Intervention: Acupressure bands + 2 mL IV saline
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 10 mg IV metoclopramide + placebo wrist bands
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo wrist bands + 2 mL IV saline
Number of subjects: 75
Study: 8275615

Group type: EXPERIMENTAL
Intervention: Valaciclovir (256U87) at doses from 100 to 1000 mg (single-dose study)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Valaciclovir (256U87) at doses from 250 to 2000 mg (multiple-dose study)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 3546605

Group type: EXPERIMENTAL
Intervention: Isoniazid (INH) therapy
Number of subjects: 10
Study: 31536384

Group type: EXPERIMENTAL
Intervention: Games-on (access to mobile games)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Games-off (no access to mobile games)
Number of subjects: 30
Study: 30655665

Group type: EXPERIMENTAL
Intervention: tiotropium/olodaterol 5/5 µg
Number of subjects: 0

Group type: COMPARATOR
Intervention: tiotropium
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study: 28622815

Group type: COMPARATOR
Intervention: Computer-delivered brief intervention (CBI)
Number of subjects: 659

Group type: COMPARATOR
Intervention: Therapist-delivered brief intervention (TBI)
Number of subjects: 659

Group type: EXPERIMENTAL
Intervention: Control group
Number of subjects: 659
Study: 25584002

Group type: EXPERIMENTAL
Intervention: Cy/GVAX followed by CRS-207 (arm A)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Cy/GVAX (arm B)
Number of subjects: 90
Study: 23473238

Group type: EXPERIMENTAL
Intervention: Multimodal coma stimulation 5-times a day (20 minutes each session)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Multimodal coma stimulation twice a day (50 minutes each session)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional physiotherapy twice daily
Number of subjects: 30
Study: 21523806

Group type: EXPERIMENTAL
Intervention: Children with SCD
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Children with SCD and cerebral infarct
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Children with SCD and acute brain ischemia
Number of subjects: 100
Study: 19759428

Group type: EXPERIMENTAL
Intervention: Yoga (YG; n=62)
Number of subjects: 291

Group type: COMPARATOR
Intervention: Wait-list control (WL; n=56)
Number of subjects: 291
Study: 16935774

Group type: EXPERIMENTAL
Intervention: EGFR tyrosine kinase inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cisplatin-based chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EGFR tyrosine kinase inhibitors plus aromatase inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dicer downregulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overexpression of Wnt genes and methylation of Wnt antagonists
Number of subjects: 0
Study: 15823768

Group type: EXPERIMENTAL
Intervention: Escin during second and third treatment periods
Number of subjects: 50

Group type: COMPARATOR
Intervention: No escin (Control) during first and fourth treatment periods
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Escin treatment
Number of subjects: 50
Study: 11486242

Group type: EXPERIMENTAL
Intervention: Estrogen‐progestogen continuous combined HRT
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study: 9647368

Group type: EXPERIMENTAL
Intervention: Oral midazolam (0.5 mg/kg, maximum 20 mg)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 123
Study: 8076565

Group type: EXPERIMENTAL
Intervention: Colonoscopy experience questionnaire (31-item, rated on a seven-point scale)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Procedures performed by the most experienced endoscopist
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Gender comparison (female vs male patients)
Number of subjects: 130
Study: 2707713

Group type: EXPERIMENTAL
Intervention: Posturographic biofeedback training
Number of subjects: 72

Group type: COMPARATOR
Intervention: Physical training (control group)
Number of subjects: 72
Study: 336132

Group type: EXPERIMENTAL
Intervention: Two-layer closure (continuous catgut to peritoneum and continuous nylon to sheath)
Number of subjects: 326

Group type: COMPARATOR
Intervention: One-layer closure (peritoneal suture line omitted)
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Patients with jaundice
Number of subjects: 326

Group type: COMPARATOR
Intervention: Non-jaundiced patients
Number of subjects: 326
Study: 29677687

Group type: EXPERIMENTAL
Intervention: Plasma from women with late onset preeclampsia
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Plasma from women with gestational hypertension (GH)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Plasma from women after normotensive pregnancy
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: BMI ≥25
Number of subjects: 3
Study: 28045554

Group type: EXPERIMENTAL
Intervention: Aerobic exercise program (27 sessions over nine weeks)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Social/art activities (control group)
Number of subjects: 19
Study: 26362236

Group type: EXPERIMENTAL
Intervention: Sandal orthotic
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Sandal
Number of subjects: 52

Group type: COMPARATOR
Intervention: Footwear conditions
Number of subjects: 52
Study: 22305632

Group type: EXPERIMENTAL
Intervention: ERN/LRPT 1g/20mg + SIMVA (10 or 20mg)
Number of subjects: 2340

Group type: COMPARATOR
Intervention: ATORVA (10, 20, 40, or 80 mg)
Number of subjects: 2340
Study: 21986305

Group type: EXPERIMENTAL
Intervention: Spinal manipulative therapy (SMT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Side‐posture positioning only (control)
Number of subjects: 40
Study: 18276803

Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil (ADV) 0.14 mg/kg
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil (ADV) 0.3 mg/kg
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil (ADV) 10 mg
Number of subjects: 45
Study: 16467761

Group type: EXPERIMENTAL
Intervention: Single immediate dose of Mitomycin C (MMC)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Delayed multi-dose regimen of Mitomycin C (MMC)
Number of subjects: 100
Study: 12830442

Group type: EXPERIMENTAL
Intervention: Short daily HD
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Long nocturnal HD
Number of subjects: 45

Group type: COMPARATOR
Intervention: Conventional thrice-weekly HD
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Quotidian HD therapy
Number of subjects: 45
Study: 10706488

Group type: EXPERIMENTAL
Intervention: High dose inhaled steroids
Number of subjects: 619

Group type: COMPARATOR
Intervention: Low dose inhaled steroids
Number of subjects: 619

Group type: EXPERIMENTAL
Intervention: Elevated IgG and/or IgA
Number of subjects: 619

Group type: EXPERIMENTAL
Intervention: Elevated IgA
Number of subjects: 619
Study: 9322351

Group type: EXPERIMENTAL
Intervention: Tropisetron 5 mg i.v. on day 1 + 2, then 10 mg p.o.
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Tropisetron 5 mg i.v. on day 1 + 2, then 10 mg p.o. + Dexamethasone 20 mg i.v. on days 1 + 2, then 4 mg i.v./p.o.
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Tropisetron 5 mg i.v. on day 1 + 2, then 10 mg p.o. + Metoclopramide 20 mg i.v. + 2 x 10 mg p.o. on day 1, then 3 x 10 mg p.o.
Number of subjects: 193
Study: 29198307

Group type: EXPERIMENTAL
Intervention: Quetiapine 25 mg film-coated tablets
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control formulation of quetiapine 25 mg film-coated tablets
Number of subjects: 24
Study: 3947001

Group type: EXPERIMENTAL
Intervention: Endolymphatic sac-mastoid shunt surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham surgery (simple mastoidectomy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study: 30103738

Group type: EXPERIMENTAL
Intervention: Patient-facing decision aid, RealRisks, and provider-facing Breast Cancer Risk Navigation Toolbox (BNAV) with standard education
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard education alone
Number of subjects: 0
Study: 27855094

Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 24910976

Group type: EXPERIMENTAL
Intervention: Topical rapamycin 0.1%
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 23278712

Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia (TH) at 33°C for 24 hours
Number of subjects: 31

Group type: COMPARATOR
Intervention: Standardized stroke unit care (control)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Endovascular cooling
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Surface cooling
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia (TH)
Number of subjects: 31
Study: 20497031

Group type: EXPERIMENTAL
Intervention: Acupuncture for 12 months
Number of subjects: 81

Group type: COMPARATOR
Intervention: Sham-acupuncture for 6 months
Number of subjects: 81
Study: 19133217

Group type: EXPERIMENTAL
Intervention: Maraviroc (300 mg, once or twice per day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maraviroc
Number of subjects: 0

Group type: COMPARATOR
Intervention: Efavirenz
Number of subjects: 0
Study: 16364669

Group type: EXPERIMENTAL
Intervention: CS-003 (200 mg, solution in distilled water)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 14605526

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 10978998

Group type: EXPERIMENTAL
Intervention: Vasodilators
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aortic valve replacement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Symptoms, left ventricular function, and response to exercise
Number of subjects: 0